Le Lézard3h
Vertex Announces FDA Approval of JOURNAVXtm (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...
Business Wire3h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...
Cannabinoids offer new hope for safe and effective pain relief
Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers ...
Armed robbery in Revesby11h
UC Reaches $740M In Research Expenditures
The University of Cincinnati and its affiliates reached $740 million in research expenditures in 2024, a 6% increase over the previous year and a ...
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published ...
clinicalpainadvisor.com13h
Longer Time to Pregnancy in SpA Linked to NSAID Use, Maternal Age
Maternal age and NSAID use during the preconception period were associated with a longer time to pregnancy among women with SpA.
Medindia16h
Neuropathy: Persistent Nerve Pain Affects 40% of Cancer Patients on Chemotherapy
Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...
Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
Chromocell Therapeutics (NYSE:CHRO) Stock Price Down 10.6% – Time to Sell?
Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report)’s share price traded down 10.6% during mid-day trading on Wednesday . The company traded as low as $2.11 and last traded at $2.20. 105,552 ...